key: cord-0716868-bzsve0ic
authors: Banerjee, M.; Pal, R.
title: Reply to letter to the editor: “COVID‐19 and the endocrine system: exploring the unexplored”. Focus on acromegaly
date: 2021-01-01
journal: J Endocrinol Invest
DOI: 10.1007/s40618-020-01470-8
sha: 0a87938852578649b0e6f7cf5d7d380547ea37b7
doc_id: 716868
cord_uid: bzsve0ic

nan

and thereby contact with health care professionals. Caregivers can be trained regarding administration of intramuscular injections at home via virtual interactions with physicians and/or online videos. Blood glucose should be periodically monitored in patients on SRLs as both improvement and worsening of glycemic control has been reported. In addition, the increased risk of QT prolongation needs to be kept in mind in an acromegaly patient on SRL who gets infected with COVID-19 and is inadvertently prescribed hydroxychloroquine [2] . Long-acting pasireotide offers good biochemical control but is also associated with dysglycemia.

Pegvisomant is a good choice in acromegaly patients with dysglycemia, however, the drug is not universally available and being exorbitantly priced, might not be accessible to patients in resource limited settings. Moreover, the drug should be used cautiously in patients with macrosomatotropinoma and compressive symptoms as an increase in adenoma size has been reported in 3% of patients started on pegvisomant. The combination of pegvisomant and SRL offers good control of disease activity, however, is associated with an increased risk of transaminitis necessitating monitoring of liver function that might not be feasible during the pandemic.

The dopamine agonist, cabergoline offers a safe and relatively inexpensive alternative to SRL and pegvisomant, however, normalization of insulin-like growth factor 1 (IGF1) is achieved in only 30% of patients and might be considered only in patients with mild elevation of IGF1. However, combining cabergoline with SRL is a reasonable option as combination therapy leads to normalization of IGF1 in nearly 50% of patients [5] .

Dose titration under the prevailing circumstances can be reliably achieved via virtual clinics, relying mostly on the clinical status, IGF1 measurement (if it can be safely arranged) and patient-reported adverse events.

COVID-19 and the endocrine system: exploring the unexplored" Focus on acromegaly

Letter to the editor: "our response to COVID-19 as endocrinologists and diabetologists

Managing common endocrine disorders amid COVID-19 pandemic

AcroCOVID: An international survey on care for acromegaly during the COVID-19 era

Place of cabergoline in acromegaly: a meta-analysis

Acknowledgements None.